Gadavist is named as an intervention in 2 current clinical trials in our Israel, USA, Germany, France, Italy, Canada, Brazil and South Korea registers. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Guerbet (1). The most-studied condition is Motor Function.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564 · ClinicalTrials.gov ↗ · Motor Function, Cognitive Function, Contrast Media
|
Phase 4 | Recruiting | Guerbet | USA, Germany, France, Italy, Canada, Brazil, South Korea, Israel |
|
The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study
NCT06854458 · ClinicalTrials.gov ↗ · Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow
|
Not applicable | Recruiting | Brigham and Women's Hospital | Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Guerbet | 1 |
| Brigham and Women's Hospital | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Israel, USA, Germany, France, Italy, Canada, Brazil and South Korea registers name Gadavist as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in Israel, 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in Italy, 1 with sites in Canada, 1 with sites in Brazil and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Guerbet (1) and Brigham and Women's Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Gadavist works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gadavist works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gadavist (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.